Sign in
Active, not recruitingPhase 4

Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis

Key facts

Who runs it
Northwestern University
Where
Chicago, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
20 people, planned
Started
24 Aug 2022
Expected to end
1 Sept 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Naproxen 500 Mg
  • Placebo
Record updated
23 March 2026

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (37)Hide the full registry criteria

Who can take part

  • Male or female >40 years of age
  • Meet ACR criteria for knee OA
  • Able and willing to provide informed consent
  • Average weekly pain in the index knee based on daily pain assessments of ≥ 4/10 and <9/10 on an 11-point NRS scale
  • Willing to discontinue current medications taken for OA pain
  • For women of child-bearing potential, willing to utilize some form of birth control or abstinence during the course of the study
  • If taking cannabinoids, have to be on a stable dose and have this maintained for the duration of the study
  • If receiving physical therapy or any non-pharmacologic modality(ies) for OA, these need to continue and remain stable for the duration of the study
  • Ambulatory
  • Have a cellphone and/or access to a computer and be able to utilize the eDiary as directed
  • Use of medications for knee OA pain on at least 4 out of 7 days per week
  • eDiary entries on at least 4 out 7 days per week during the observation period
  • Sub-Group Criterion (≥12 participants): Variability of average daily pain in the index knee during the observation period of ≥ 2 points on the NRS scale on at least 4 occasions

Who cannot take part

  • Previous history of GI bleed
  • Use of recreational drugs
  • Index knee cannot have had previous joint replacement surgery
  • Corticosteroid injection in the index knee in the past 3 months
  • History of intolerance or allergic reaction to NSAIDs
  • History of myocardial infarction in last 6 months
  • Coexisting congestive heart failure or symptomatic atherosclerotic heart disease
  • Use of oral anticoagulants other than aspirin ≤ 325 mg for cardiac prophylaxis
  • Uncontrolled hypertension
  • Any medical condition which in the judgement of the investigator would make it inappropriate for the participant to enroll in the study
  • Participation in another clinical trial other than one for covid or an observational and non-interventional study
  • Any acute or chronic pain condition which would interfere with the evaluation of knee pain
  • Renal insufficiency resulting in serum creatinine > 1.5 mg/dL
  • Use of heparin or injectable anticoagulant
  • Fibromyalgia
  • Inflammatory arthropathies of any sort
  • Chronic back pain in which pain level is greater than the OA pain
  • Use of walker or other aid for walking other than a single cane
  • Hip pain on the ipsilateral side equal to or greater than the knee pain in the index joint
  • Arthroscopy within the past 6 months
  • Injection of hyaluronate in the index knee in the past 6 months
  • Injection of any biologic agent in the index in the past 12 months
  • Nerve ablation for the treatment of pain in the index knee
  • Pregnant, nursing or planning to become pregnant during length of study

Where in United States

  • Northwestern University Feinberg School of MedicineChicago, United States

About the trial

What the trial wants to find out

This is a pilot study with a 4-period double-cross-over design evaluating a treatment with non-steroidal anti-inflammatory drugs (NSAIDs) in people with painful knee osteoarthritis.

The 2 groups in the trial

  • Cross-over Treatment: Initial treatment with naproxenTreatment being tested

    There will be a 4 period cross-over: 2 weeks of treatment with IP, followed by 2 weeks of washout, and this repeated 3 more times. Treatment will be such that all participants will receive 2 treatment periods with naproxen and 2 treatment periods with placebo. The order of treatment will be randomized and the treatment allocation and IP will be blinded.

    Treatment: Naproxen 500 Mg and Placebo

  • Cross-over Treatment: Initial treatment with placeboTreatment being tested

    There will be a 4 period cross-over: 2 weeks of treatment with IP, followed by 2 weeks of washout, and this repeated 3 more times. Treatment will be such that all participants will receive 2 treatment periods with naproxen and 2 treatment periods with placebo. The order of treatment will be randomized and the treatment allocation and IP will be blinded.

    Treatment: Naproxen 500 Mg and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
N of 1 Pilot Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis
Record updated
23 March 2026